Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology

Fibromyalgia syndrome (FMS) is a chronic condition with unknown aetiology. The pathophysiology of the disease is incompletely understood; despite advances in our knowledge with regards to abnormal central and peripheral pain processing, and hypothalamo–pituitary–adrenal dysfunction, there is no clear specific pathophysiological therapeutic target. The management of this complex condition has thus perplexed the medical community for many years, and several national and international guidelines have aimed to address this complexity. The most recent guidelines from European League Against Rheumatism (EULAR) (2016), Canadian Pain Society (2012), and The Association of the Scientific Medical Societies in Germany (AWMF) (2012) highlight the change in attitudes regarding the overall approach to FMS, but offer varying advice with regards to the use of pharmacological agents. Amitriptyline, Pregabalin and Duloxetine are used most commonly in FMS and though modestly effective, are useful adjunctive treatment to non-pharmaceutical measures.


Introduction
Fibromyalgia syndrome (FMS) is a chronic condition characterised by generalized body pain, fatigue, sleep disturbance, impaired cognition, and anxiety with unknown aetiology. Potential causes include genetic, neurologic, psychologic, sleep and immunologic factors [1]. Fibromyalgia has an estimated prevalence of 0.5% to 5.8% in North America and Europe [2]. The pathophysiology of the disease is not clearly understood, although abnormality in pain processing at various levels (peripheral and central), sleep impairment, dysregulation of the hypothalamo-pituitary-adrenal axis, and abnormalities of the autonomic nervous system have been identified as contributory factors. Despite our increased understanding of the condition, there are no objective diagnostic tests. Diagnosis is often made by exclusion of other conditions such as neurological syndromes and depression. This lack of a single unifying pathophysiology is mirrored by a complex and non-specific approach to management.
The first clinical criteria for the diagnosis of FMS was set in 1990 by the American College of Rheumatologist (ACR) [3]. It was based on widespread body pain (defined as the pain affecting both sides of the body above and below the waist) for at least three months plus tenderness in at least 11 out of 18 tender points. In 2010, these criteria were updated to change the focus towards a subjective widespread body pain index (WPI) and symptom severity scale (SS), taking into account cognitive symptoms, sleep, fatigue and additional somatic symptoms [4].
Despite our greater understanding of the disease, there is no definitive treatment for FMS and various guidelines for treatment exist, which are at time contradictory in their advice. The approach to managing FMS has evolved over recent years, as reflected by recently updated guidelines published by European League Against Rheumatism (EULAR) [5]. Increasingly, there is a focus on non-pharmacological therapies for FMS, such as cognitive behavioural therapy, exercise therapy, hydrotherapy, and acupuncture. Although these advances may have aided the management of FMS, providing clinicians and patients with alternative therapy avenues to pursue, pharmacology remains the mainstay of therapy. Therapeutic classes and targets of pharmacologic therapy in FMS are varied, including classical analgesic therapies such as opiates, and ranging to antidepressants, anticonvulsants, and others. This wide range of therapies often leads to confusion in the clinic, and the evidence supporting one therapy over another is limited. This is reflected in the guidance, which offers evidence for the potential utility of each class of pharmacological intervention, but does not necessarily support one form over another and certainly does not provide a treatment hierarchy. Compounding these difficulties, there is also a significant degree of variability between the guidance.
In this paper, we will review the most recent national and international guidelines for the management of fibromyalgia, with a particular focus on the pharmacological agents. We will set out the evidence for the use of each class of pharmacological agent derived from each guideline, and form a synthesis of the evidence with the aim of assisting clinicians in gaining an overview of each intervention based on the agent, rather than divided by guideline. The process and quality of the guideline drafting process will also be assessed.

The Guidelines
The EULAR 2016 guidelines [5] were developed by 18 members from 12 European countries including clinicians, no-clinical scientists, patient representatives, and allied health professions. The guideline is based upon synthesis of systematic reviews (with or without meta-analysis) with pain as the primary outcome, although fatigue, sleep, and daily function were also used as secondary endpoints. The authors used the Grading Recommendations Assessment, Development, and Evaluation system (GRADE) for making recommendations, with the strength of recommendations based on desirable and undesirable effects. This is a four-point scale: strong for/weak for/weak against/strong against ( Table 1). All participants then voted on the level of agreement. In their 10 recommendations, exercise therapy has been given the highest level of recommendation which is a stark difference from the previous guideline [6] where pharmacological treatment was considered to be the focus of therapy. Initial management should involve patient education and focus on nonpharmacological therapies. In non-responsive patients, pharmacological therapies should be added especially to those with sleep or mood disturbances. The 2012 Canadian guideline [7,8] was developed by the Canadian Fibromyalgia Guideline Committee (CFGC), comprising of 12 members of relevant healthcare professionals, a patient representative, an external international expert and a research coordinator. The literature search covered a 20-year period (1990-2010) and a broad scope of evidence was considered not limited to randomised controlled trials (RCTs). The recommendations were then submitted to the 35 members who form the National Fibromyalgia Guideline Advisory Panel. Recommendations were graded according to the classification system of the Oxford Centre for Evidence Based Medicine [9]. The primary recommendation of these guidelines indicates a paradigm shift in terms of the diagnosis and management of fibromyalgia, with an emphasis on the delivery of care in the community. Greater patient involvement in terms of educations and self-management was also highlighted. The guideline acknowledges that pharmacological therapy, even at best, is only modestly effective, but that regular physical activity should be considered the cornerstone of treatment, with the highest level of recommendation.
The German guideline [10] was developed by the Association of the Scientific Medical Societies in Germany (AWMF) which is a 12-member committee comprising of representatives from 10 scientific societies and two patient self-help organizations. The process was initiated and coordinated by the German Interdisciplinary Association of Pain Therapy (DIVS). The recommendations are based on a systematic review of the literature (all controlled studies, systematic reviews and meta-analysis) up to 31 December, 2010. In the AWMF guidelines, where no high-quality evidence was reported to be available, uncontrolled trials and case series were reviewed and expert opinion was sought. Level of evidence was based on the Oxford Centre for Evidence Based Medicine system [11], and the grading of the recommendations based on the German Programme for Disease Management guidelines [12] ( Table 1). The recommendations are made based on the efficacy of the intervention, associated risks, patient preference and practicability/applicability (i.e., was the drug approved for therapy of FMS and/or its common comorbidities in German). The AWMF guideline highlights the importance of partnership with patients and also developing realistic aims of therapy based on informed-decision making, local availability, cost and patient presences. The summary recommendation is strongly in favor of physical activity treatment options, such as exercise and psychological therapies. Continuous pharmacological treatment is only recommended where the benefits are sustained.
The comparison of the categorisation of the evidence and recommendations of the three guidelines is listed in Table 1.

Pharmaceutical Therapies
Each of the three guidelines was interrogated for its source data, and the levels of evidence for each pharmaceutical agent/class evaluated based on the included articles. Unless stated, the guidelines used systematic review articles and meta-analysis as the basis of their recommendations, although the robustness of these reviews and the quality of the included studies was variable. The summaries of the article are included in Appendix A. The choice of pharmaceutical therapies in treating patient with FMS should be guided by the patient's clinical features, side effect profile, and response. FMS patients started on pharmaceutical therapies should be reviewed frequently and the dose titrated up based upon the patient's response. Where therapy has not demonstrated a positive effect, or where side effects are prominent, treatment should be discontinued.

Amitriptyline
Amitriptyline (AMT) is a tricyclic antidepressant known to inhibit both serotonin and noradrenalin reuptake, and has long been used for the management of neuropathic pain and FMS. The AWMF guidelines assessed 12 studies in their meta-analysis, whereas the Canadian guidelines examined only two systematic reviews, whilst EULAR examined five review articles (Table A1, Appendix A).
AMT has received a strong recommendation from AWMF (10-50 mg/daily), while the EUALR guidelines suggest only low dose may be beneficial, although with a high degree of consensus. The Canadian guidelines take a much more a general approach to AMT, and recommend that all categories of antidepressants, including SSRI and NSRI may be used for the treatment of FMS depending on the individual efficacy of the drug, physician's knowledge, patient's characteristics, and cost. Nishishinya et al. also concluded that AMT 25 mg/day improved pain, sleep and fatigue at 6-8 weeks with no evidence for 50 mg/day [13].

Anticonvulsants
Pregabalin (PGB) and Gabapentin (GBP) are both structurally similar to the neurotransmitter γ-aminobutyric acid (GABA), although neither drug has activity in GABA's neuronal system. Their analgesic effect is linked to their ability to bind to voltage-gated calcium channels in the central nervous system (CNS) [14]. An eight-week, double-blind, randomised clinical trial of 529 patients with FMS demonstrated the efficacy of PGB at different doses (300 mg, 450 mg), demonstrating a more than 50% improvement in pain with PGB 450 mg/day. Other domains including sleep quality, fatigue, and health related quality of life also showed improvement [15]. In a Cochrane review, a daily dose of 600 mg produced no better outcome than 450 mg/day for any outcome measures [16]. The recommendations across the guidelines with regards to the use of these drugs are somewhat variable; the CPS recommends using anticonvulsants with data derived from level 1 evidence (Table A2, Appendix A), while AWMF recommends using PGB (150 to 450 mg/day) if treatment with AMT is not possible, and refrains from making any recommendations with regards to GBP. EULAR guideline analyses nine review articles on PGB (n = 1481 to 3334) and one clinical trial on gabapentin (n = 150). EULAR recommends use of PGB (weak for), and gabapentin for research purposes only.
Use of PGB and GBP may be limited by their side effect profile such as dizziness, somnolence, weight gain, peripheral oedema, and negative neurocognitive effects [17].

Serotonin-Noradrenalin Reuptake Inhibitors (SNRI)
Serotonin (5-HT) and noradrenalin have been implicated in the mediation of the descending pain inhibitory pathways [18], which have in turn been linked to the pathophysiology of FMS. Patients with FMS have been found to have decreased concentration of 5-HT and its precursor (tryptophan) in serum and cerebrospinal fluid [19]. Serotonin is implicated in psychiatric disorders such as depression and anxiety [20], and is theorized to have a role in pain threshold and stage 4 sleep [19].
Duloxetine (DLX) has a five-fold stronger effect on serotonin than on noradrenalin [21]. AWMF analyses five RCTs with 1157 participants, whilst EULAR uses eight systematic reviews with 443 to 2249 participants (Table A5, Appendix A). AWMF recommends DLX (60 mg/day) for patients with comorbid depressive disorder, with or without general anxiety disorders. This recommendation is also endorsed in the CPS and EULAR guidelines. DLX dose and length of therapy is guided by patient response and side effect profile. However, DLX 20-30 mg/day has not shown to be effective, and no difference was found between 60 mg/day compared to 120 mg/day [22].
Milnacipran (MLN) has three-fold stronger effect on noradrenalin than serotonin. It is recommended by EULAR (seven systematic reviews) and has been shown to be effective [21,[23][24][25][26], though DLX was found to be superior to MLN in reducing pain and sleep problems [27]. AWMF guidelines do not recommend the use of MLN. This is based on low quality evidence, with low acceptance amongst patients and high risks of side effects. There is not enough available evidence with regards to the use of other agents such as venlafaxine in the management of FM.

Selective Serotonin Reuptake Inhibitors
A recent Cochrane review concluded that there was no unbiased evidence with regards to superiority of SSRIs to placebo in treating the key symptoms of fibromyalgia (pain, fatigue and sleep problems), however they might be considered for treating depression in this group of patients [28]. National and international guidelines are mixed with regards to their recommendations on SSRIs. EULAR guidelines are derived from seven systematic reviews, whilst AWMF uses eight RCTs in their meta-analysis (Table A4, Appendix A). EULAR does not recommend their use, whereas the Canadian and AWMF guidelines do recommend their use. Fluoxetine 20-40 mg/day or paroxetine 20-40 mg/day can be considered for a limited period of time in comorbid depressive/anxiety disorders [29,30]. Citalopram was ineffective in management of FMS in a small RCT of 40 patients [31].

Opioids
Use of strong opioids has been discouraged in the treatment of FMS. There is a deficit in opioid mediated descending anti-nociceptive activity in patients with FMS, with increased level of endogenous opioids in the CSF [32] and decreased central µ-opioid receptor availability [33], which may explain the lack of effectiveness of exogenous opioids in this group of patients.
Tramadol is a weak opioid with combined µ-receptor agonist and 5-HT and norepinephrine reuptake inhibition activity [34]. It is this latter action that is possibly the key in its efficacy in FMS compared to other opioids. The efficacy of tramadol in FMS has been studied in number of trials [35][36][37][38], although the long-term efficacy and the optimal dose of tramadol have not been addressed by the clinical trials. EULAR guidelines use two meta-analysis, Canadian guidelines 2RCTs whilst AWMF uses only one RCT (Table A6, Appendix A). Tramadol is recommended by EULAR and the Canadian guidelines, whereas AWMF refrain from making any recommendations on the basis of lack of data.

Cyclobenzaprine
Cyclobenzaprine is a centrally acting muscle relaxant which is structurally related to TCA, and which was first developed as an antipsychotic therapy [39]. The EULAR guideline recommends the use of cyclobenzaprine (weak for, 75% agreement) based on one systematic review involving 312 patients (Table A3, Appendix A) [40]. Overall, patients treated with cyclobenzaprine were three times more likely to report overall improvement but there was no improvement on fatigue. In total, 85% of patients experienced side effects and only 71% completed the studies. The AWMF guidelines do not recommend the use of this medication on the basis of lack of license for its use, and risk of side effects (confusion, skin lesions, liver toxicity).

Cannabinoids
Cannabinoid molecules have been shown to have analgesic properties as well as sleep promoting affects [41], hence there has been increasing interest in their use in pain management. The endogenous cannabinoids and their receptors have been localized to multiple levels of nervous system (both peripheral and central) [42], and have an acknowledged role in helping to regulate neural process associated with pain perceptions, mood, appetite and memory [43]. The Canadian guidelines recommend the use of pharmacological cannabinoids, particularly in the setting of sleep disturbance, although it has not received any recommendations by AWMF and EULAR. There is also concern with regards the risk of abuse [44], there is a general need for further research into their use.

Analgesic Treatments (Non-Steroidal Anti-Inflammatory (NSIADs) and Acetaminophen)
Use of NSIADs for the management of FMS symptoms are not recommended by EULAR and AWMF. These recommendations come from a small number of studies (Table A7 Appendix A). A recent Cochrane review on NSAIDs in FMS also came to the same conclusion [45]. However, the Canadian guidelines, though not directly supporting their use in FMS, recommend using this group of drugs with the lowest possible dose for the shortest possible times in concurrent conditions such as osteoarthritis. Acetaminophen's actions, such as modulating the endogenous cannabinoid system [46], and serotonin receptor agonist [47], may be beneficial in FMS. There is no direct evidence with regards to the use of acetaminophen in FMS though it has been used in combination with tramadol [35]. Table 2 provides the list of medications that are not recommended for use in FMS, and which are not discussed in this paper.

Discussion
Discordance between the guidelines on recommendations for pharmacological treatments for of FMS is primarily due to lack of high-quality randomized control trials in FMS, hence the guidelines rely on lower-quality evidence and expert consensus. Perhaps most tellingly, the latest guidelines all recommend non-pharmacological therapies, such as exercise, with a greater level of confidence than pharmacological agents, perhaps in part due to low risk of side effects and the generic health benefit of exercise. Despite this, the pharmacological treatment of FMS has an acknowledged role, especially where symptoms of or a concurrent diagnosis of depression is prominent.
One potential source of divergence in the guidelines in in the difference between their respective committees. The EULAR committee is formed of experts from 12 European countries with different health care systems, populations needs, and to some degree availability of therapies. EULAR also focuses mainly on systematic reviews (with or without meta-analysis), which provide the highest level of evidence, although narrowing the breadth of the guidance. AWMF, however, uses clinical trials as well as the systematic reviews, thus potentially capturing a greater number of admittedly lower quality studies. The Canadian guidelines uses original studies, systematic reviews, and evidence-based guidelines, and was perhaps the broadest approach to evidence gathering, although the number of included studies was actually less than that of the AWMF guidelines.
Further to the methodological differences between the guidelines, the divergence of the guidelines is also compounded by the variability with regards to the licensing of drugs in FMS. In the US, the FDA approved medications for FMS include duloxetine, MLN, and PGB, whereas opioids are not approved for treatment of fibromyalgia. Only PGB and duloxetine had Health Canada approval for management of FMS, and the use of other drugs is effectively "off-label" (use the guidance ref on line). In Germany, no drug is specifically licensed for FMS. Each of these factors may influence the prescribing patterns of clinicians managing patients included in the contributory data, and in the future of clinical practice.
Additionally, the guidelines do not offer information based on the outcomes for each of the six OMERACT core domains (pain, sleep disturbance, fatigue, affective symptoms, functional deficit, and cognitive impairment) [48], which would have allowed direct comparison of the evidence between studies and pertaining to individual disease components. This analysis would in turn help clinicians provide individualized care for patients exhibiting differing manifestations of FMS.
The guidelines are however all in agreement that therapy should be tailored to the individual needs of the patient, and that non-pharmacological therapy should be encouraged in the first instance. This is again reiterated in the Canadian guidelines, where a shift to community based care (general practice) is emphasized, also highlighting the fact that the ACR diagnosis guidelines (1990 and 2010) were mainly designed for research purposes.
EULAR recommends using DLX, PGB, or tramadol (in combination with paracetamol) in severe pain, and that AMT, cyclobenzaprine, or PGB should be considered at night for sleep problems. This is in contrast to the Canadian guidelines, which make only general recommendations on groups of drugs, rather than focusing on a specific agent. Despite the guidelines stating level 1 evidence for antidepressant medications (TCA, SSRI, and SNRI) and anticonvulsants, it does not provide enough information to the prescriber with the regards to the choice of medication, optimum dosage, and the duration of therapy.
The AWMF (2012) guidelines recommend AMT as a first-line pharmacological treatment, with duloxetine as a second-line treatment in patients who cannot tolerate AMT and have concurrent depressive disorder. The AWMF guidelines are also more explicit with regards the use and duration of the pharmacological therapy; recommending a trial treatment of at least 6 months, after which, if no effect is observed, the therapy should be stopped. This is based on the maximum duration of RCT study with AMT, Duloxetine and Pregabalin being 6 months [10].
Canadian 2012 guidelines, as well as shifting the diagnosis and management of FMS to the primary care, support the use of combination of non-pharmacological and drug therapy in fibromyalgia.
However, their recommendation with regards to the pharmacological therapy is vague and depends heavily on the expertise of the reader.
Despite advances in the understanding of the pathophysiology of FMS, the pharmacological management has remained complex and poorly evidenced. What is clear is that an individualized approach to patient care is imperative, and that pharmacological therapy should be considered as an adjunct to non-pharmacological intervention. Where medication is deemed necessary, it should be targeted specifically towards the specific symptoms of the FMS in the individual patient, and if no improvement is observed after a reasonable trial period, should be discontinued. It is also important to note the risks of side effects of these medications, which may add to the complexity of the picture ( Table 3). There is currently no evidence to support the use of multiple therapies for FMS, although this is commonly seen in clinical practice. Concerns regarding licensing should be addressed by regulatory bodies, especially where there are concerns regarding the widespread use of "off-license" therapies.

Conflicts of Interest:
The authors declare no conflict of interest.

Appendix A
List of evidence used to formulate the guidelines.  [58] Randomised controlled trial showed that CBT was superior to pharmacolical therapy (cyclobenzaprine) in FMS. Randomised controlled trial of AMT (25 mg) and Naproxen, which showed AMT was associated with significant improvement in all outcomes. Goldenberg, D. et al. 1996 [29] Randomised double blind cross-over trial of AMT (25 mg) and Fluoxetine (20 mg) showed both are effective and they work better in combination in FMS.
Hannonen, P. et al. 1998 [61] Randomised double blind placebo controlled study on AMT and moclobemide showed that AMT was effective in FMS (general health, pain and sleep quality). Cochrane review PGB demonstrates a small benefit in reducing pain and sleeping problems with no substantial effect on fatigue compared to placebo.
Study drop-out rates due to adverse events were higher with PGB use compared with placebo.
Siler, A.C. et al. 2011 [69] Systematic review, 5 RCTs on PGB and 1 on gabapentin. PGB and gabapentin are modestly effective in treatment of fibromyalgia though their long-term safely and efficacy remains unknown.
Roskell, N.S. et al. 2011 [70] Meta-analysis, PGB 3 RCTs, Gabapentin 1 RCT. A 30% pain reduction was observed in patients treated with gabapentin and PGB (300 mg and 450 mg). There was also significant risk of discontinuation due to adverse events. Meta-analysis on treatment of FM with gabapentin and PGB. There was strong evidence for reduction of pain, improve sleep and quality of life but not for depressive symptoms.
Moore, R.A. et al 2009 [16] Cochrane review, on PGB for acute and chronic pain. Pregabalin was effective at doses of 300 mg, 450 mg and 600 mg in treating of variety of pain conditions including FMS (5 studies).
Häuser, W. et al. 2010 [21] Comparative efficacy and harms of DLX, MLN, in PGB in FMS. The three drugs are superior to placebo except DLX for fatigue, MLN for sleep disturbance and PGB for depressed mood.
Recommendations for PGB is based on rather weak evidence. Mean pain reduction between 9% to 15%. Treatment with anticonvulsant medications should begin with the lowest possible dose followed by up titration. Level 1, Grade A.

Hauser, W. et al. 2009 [17]
A meta-analysis of randomized controlled trials on treatment of fibromyalgia syndrome with gabapentin and PGB (6 RCT, 8733 participants) showed both drugs were associated wig small but significant pain reduction, improved sleep function but did not significantly affect the level of depression.
Moore, RA. et al. 2009 [16] As Per EULAR Systematic review including 5 placebo-control trials (n = 312). The odds ratio for global improvement was 3.0 (95% CI 1.6-5.6) with no improvement in fatigue or tender points in FM.

AWMF
List of studies included in the meta-analysis Bennett, R.M. 1988 [75] Double blind control study, comparison of cyclobenzaprine and placebo showed significant reduction in total tender points and fatigue.
Negative recommendation. strong consensus. Level of evidence 2a.
Carette, S. et al. 1994 [55] Randomised double blind trial to compare relative efficacy and safety of AMT and cyclobenzaprine. Confirm short-term efficacy and safety of both.
Hamaty, D. 1989 [76] Double blind, cross-over study on plasma endorphin, prostaglandin and catecholamine profile of patients treated with cyclobenzaprine compared to placebo.
Reynolds, M. 1991 [77] Double blind, placebo controlled cross-over design on the effects of cyclobenzaprine showed improvement in fatigue and total sleep with no benefit on pain. Meta-analysis and review of antidepressants treatment of fibromyalgia including citalopram and fluoxetine did not show significant difference with placebo however only 2 trials were included for analysis.  [86] Meta-analysis (as per EULAR)  [49] Meta-analysis, ten AMT (n = 612), four DLX (n = 1411) and five MLN (n = 4129) studies, showed that 3 drugs were superior to placebo except DLX for fatigue, MLN for sleep and AMT for quality of life. AMT was superior to DLX and MLN for pain reduction, sleep disturbance and quality fif life improvement. DLX was superior to MLN in pain reduction, sleep disturbance and quality f life improvement. MLN was superior to DLX in reducing fatigue.
Perrot, S. et al. 2014 [52] Meta-analysis. DLX showed a statistically significant improvement in reducing pain, sleep disturbance, fatigue, affective symptoms, functional deficit and cognitive impairment. MLN improved pain but had no effect on sleep disturbance, fatigue, affective symptoms and functional deficit.
Häuser, W. et al. 2010 [21] Review study on DLX, MLN and PGB (17 studies, n = 7739). The three drugs were superior to placebo for all outcomes. DLX and PGB were superior to MLN in reduction of pain and sleep disturbance, DLX was superior in reducing depressed mood, MLN and PGB were superior in reducing fatigue.
Choy, E. et al. 2011 [66] A systematic review and mixed treatment comparison, confirmed the efficacy of PGB and SNRIs in treatments of FMS.
Häuser, W. et al. 2013 [27] Cochrane review (n = 6038). 5 studied on Duloxetine, 5 studies on MLN. Both drugs provide a small benefit over placebo with no improvement in fatigue and quality of life (QOL).
Sultan, A. et al. 2008 [87] Systematic review. DLX is equally effective for the treatment of peripheral diabetic neuropathy and FM. Doses higher than 60 mg do not provide additional pain relief, but cause slightly more withdrawal due adverse effects.
Lunn, M.P. et al. 2014 [22] Cochrane review (n = 2249). Duloxetine in short-term (12 weeks) and long-term (  Randomised double-blind, placebo controlled trial (n = 207). DLX (120 mg/day) is effective and safe in treating any symptoms of FM. 120 mg/day resulted in more than 50% pain reduction in 3 months.   [37] Double blind cross-over experiment (n = 12) showed Tramadol to be beneficial in pain relief Randomised double blind placebo controlled trial, (n = 164) showed that tenoxicam + bromazepan can be effective in some patients with FM however the improvement was no clinically nor statistically significant compared to placebo.
Yunus, MB, et al. 1989 [98] Double blind placebo controlled trial on ibuprofen(n = 46) did not show any benefit compared to placebo.

Canadian guideline 2012
Rao, SG. et al. 2004 [99] As fibromyalgia is a central pain syndrome, classes of drugs such as NSAIDs and opioids which act peripherally are ineffective.
In the event that NSAIDs are prescribed, particularly with associated conditions, they should be used for the shortest period of time and lowest possible dose. (Level 5 grade D). Tannenbaum, H. et al.